Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-STROKE: Asundexian for prevention of ischemic stroke after acute non-cardioembolic ischemic stroke or high-risk TIA
jRCT2041220133Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Noncardioembolic stroke (NCES) and transient ischaemic attack (TIA) comparing Asundexian with Placebo (2 arms). Primary endpoints: Time to first occurrence of ischemic stroke and Time to first occurrence of ISTH major bleeding. Started Jan 2023; status: completed.
02
Drugs
asundexian
03
Conditions
Noncardioembolic stroke (NCES)transient ischaemic attack (TIA)
Beyond the preview
Go deeper on jRCT2041220133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220133.